• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lu 标记的环天冬氨酰-甘氨酰-精氨酸肽标记的碳纳米球作为肿瘤靶向放射性纳米探针。

Lu-labeled cyclic Asn-Gly-Arg peptide tagged carbon nanospheres as tumor targeting radio-nanoprobes.

机构信息

Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.

Analytical Chemistry Division, Bhabha Atomic Research Centre, Mumbai, India.

出版信息

J Pharm Biomed Anal. 2018 Apr 15;152:173-178. doi: 10.1016/j.jpba.2018.01.052. Epub 2018 Jan 31.

DOI:10.1016/j.jpba.2018.01.052
PMID:29414010
Abstract

This study explores the potential of Lu-labeled carbon nanospheres as radio-nanoprobes for molecular imaging and therapy. The carboxyl functionalized surface of carbon nanospheres (CNS) was conjugated with [Gly-Gly-Gly-c(Asn-Gly-Arg)], G3-cNGR peptide through amide bond for targeting tumor vasculature and with [2-(4-Aminobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid], p-NH-Bz-DOTA for chelation with Lu. The nanosphere-peptide conjugate, DOTA-CNS-cNGR, was characterized by dynamic light scattering and zeta potential measurements, IR and UV experiments and did not show any in vitro cytotoxicity. The pharmacokinetics and biodistribution of Lu-labeled nanosphere-peptide conjugate, Lu-DOTA-CNS-cNGR was compared with Lu-DOTA-CNS (without the peptide) as well as with Lu-DOTA-cNGR (without carbon nanospheres). The radiolabeled nanosphere-peptide conjugate exhibited higher tumor accumulation than nanosphere-free radiolabeled peptide. The accumulation of the two radiolabeled probes in the tumor reduced to half during blocking studies with unlabeled G3-cNGR peptide. Lu-DOTA-CNS exhibited higher tumor uptake than Lu-DOTA-CNS-cNGR but rapid clearance of the latter nanoprobe from non-target organs resulted in significantly higher (p < 0.05) tumor-to-blood and tumor-to-muscle ratios at 24 and 48 h p.i. It is evident from this study that carbon nanospheres conjugated to specific vectors shall form an important part of targeted radionanomedicine in future.

摘要

本研究探讨了 Lu 标记的碳纳米球作为放射性纳米探针用于分子成像和治疗的潜力。通过酰胺键将碳纳米球(CNS)的羧基功能化表面与 [Gly-Gly-Gly-c(Asn-Gly-Arg)],G3-cNGR 肽缀合,用于靶向肿瘤血管,并与 [2-(4-氨基苄基)-1,4,7,10-四氮杂环十二烷四乙酸],p-NH-Bz-DOTA 螯合 Lu。纳米球-肽缀合物,DOTA-CNS-cNGR,通过动态光散射和zeta 电位测量、IR 和 UV 实验进行了表征,并且没有显示出任何体外细胞毒性。与 Lu-DOTA-CNS(无肽)和 Lu-DOTA-cNGR(无碳纳米球)相比,比较了 Lu 标记的纳米球-肽缀合物 Lu-DOTA-CNS-cNGR 的药代动力学和生物分布。与无肽的放射性标记纳米球肽缀合物相比,放射性标记的纳米球肽缀合物在肿瘤中的积累更高。在使用未标记的 G3-cNGR 肽进行阻断研究时,两种放射性探针在肿瘤中的积累减少到一半。Lu-DOTA-CNS 的肿瘤摄取量高于 Lu-DOTA-CNS-cNGR,但后者纳米探针从非靶器官的快速清除导致肿瘤与血液和肿瘤与肌肉的比值在 24 和 48 h p.i. 时显著升高(p < 0.05)。从这项研究中可以明显看出,与特定载体偶联的碳纳米球将成为未来靶向放射纳米医学的重要组成部分。

相似文献

1
Lu-labeled cyclic Asn-Gly-Arg peptide tagged carbon nanospheres as tumor targeting radio-nanoprobes.Lu 标记的环天冬氨酰-甘氨酰-精氨酸肽标记的碳纳米球作为肿瘤靶向放射性纳米探针。
J Pharm Biomed Anal. 2018 Apr 15;152:173-178. doi: 10.1016/j.jpba.2018.01.052. Epub 2018 Jan 31.
2
An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.通过与胆囊收缩素受体结合评估¹⁷⁷Lu标记的环CCK类似物肽的肿瘤靶向能力。
J Pharmacol Sci. 2016 Jul;131(3):209-14. doi: 10.1016/j.jphs.2016.06.006. Epub 2016 Jun 30.
3
Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.布洛芬作为白蛋白结合物对 Lu 标记的布洛芬结合的促黑激素肽的黑色素瘤靶向特性的影响。
Mol Pharm. 2024 Aug 5;21(8):4004-4011. doi: 10.1021/acs.molpharmaceut.4c00369. Epub 2024 Jul 7.
4
Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.用90Y和177Lu标记的DOTA衍生铃蟾肽类似物的比较研究:体内外评价
Nucl Med Biol. 2009 Aug;36(6):591-603. doi: 10.1016/j.nucmedbio.2009.03.006.
5
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.聚乙二醇化精氨酸-甘氨酸-天冬氨酸肽:64铜标记及脑肿瘤αvβ3整合素表达的正电子发射断层显像
J Nucl Med. 2004 Oct;45(10):1776-83.
6
A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.一类新型的基于 PentixaFor 和 PentixaTher 的治疗诊断一体化药物,具有增强的 CXCR4 靶向效率。
Theranostics. 2020 Jul 9;10(18):8264-8280. doi: 10.7150/thno.45537. eCollection 2020.
7
Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.潜在治疗性放射性示踪剂:177Lu 标记的环状 RGDfK 二聚体的制备、生物分布和代谢特征。
Amino Acids. 2010 Jun;39(1):111-20. doi: 10.1007/s00726-009-0382-0. Epub 2009 Nov 26.
8
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.降低90Y和177Lu标记的α-黑素细胞刺激激素肽类似物的肾脏摄取。
Nucl Med Biol. 2006 Aug;33(6):723-33. doi: 10.1016/j.nucmedbio.2006.06.005.
9
Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.血浆蛋白结合配体的合成、放射性标记及表征:调节(放射性)药物药代动力学性质的潜在工具
Bioconjug Chem. 2017 Sep 20;28(9):2372-2383. doi: 10.1021/acs.bioconjchem.7b00378. Epub 2017 Sep 12.
10
Preclinical evaluation of new GnRH-I receptor radionuclide therapy with Lu-peptide tracer.新型促性腺激素释放激素-I受体放射性核素疗法(使用镥标记肽示踪剂)的临床前评估
J Labelled Comp Radiopharm. 2019 Jun 15;62(7):310-320. doi: 10.1002/jlcr.3742. Epub 2019 Jun 13.

引用本文的文献

1
In Vitro Assessment of Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer.镥标记的曲妥珠单抗靶向介孔碳@二氧化硅纳米结构用于治疗HER2阳性乳腺癌的体外评估
Pharmaceuticals (Basel). 2024 Jun 5;17(6):732. doi: 10.3390/ph17060732.
2
In Vivo Imaging of Acute Hindlimb Ischaemia in Rat Model: A Pre-Clinical PET Study.大鼠模型急性后肢缺血的体内成像:一项临床前PET研究。
Pharmaceutics. 2024 Apr 15;16(4):542. doi: 10.3390/pharmaceutics16040542.
3
Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies.
用于血管生成成像的放射性标记基于NGR的异二聚体:临床前研究综述
Cancers (Basel). 2023 Sep 7;15(18):4459. doi: 10.3390/cancers15184459.
4
NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review.基于 NGR 的放射性药物用于血管生成显像的临床前评价。
Int J Mol Sci. 2023 Aug 11;24(16):12675. doi: 10.3390/ijms241612675.
5
Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.放射性标记纳米粒子的方法(第三部分):治疗用途。
Biomolecules. 2023 Aug 12;13(8):1241. doi: 10.3390/biom13081241.
6
Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.钪-44:肿瘤相关血管生成中的诊断可行性。
Int J Mol Sci. 2023 Apr 17;24(8):7400. doi: 10.3390/ijms24087400.
7
Therapeutic Performance Evaluation of Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology.双标记氨肽酶N(APN/CD13)亲和性NGR基序([Bi]Bi-DOTAGA-cKNGRE)在实验性肿瘤模型中的治疗性能评估:肿瘤学的珍贵定制方案
Pharmaceutics. 2023 Feb 1;15(2):491. doi: 10.3390/pharmaceutics15020491.
8
Synthesis and comparative evaluation of Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes.合成及比较评价 Lu 标记的 PEG 和非 PEG 变体肽作为 HER2 靶向探针。
Sci Rep. 2022 Sep 20;12(1):15720. doi: 10.1038/s41598-022-19201-9.
9
Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology.用于生物医学应用的放射性标记纳米材料:纳米技术时代的放射性药物学。
EJNMMI Radiopharm Chem. 2022 Apr 25;7(1):8. doi: 10.1186/s41181-022-00161-4.
10
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.基于肽的靶向肿瘤治疗与成像策略
Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481.